Hims & Hers Health, Inc. (HIMS) reported $586.01 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 110.7%. EPS of $0.20 for the same period compares to $0.05 a year ago.
The reported revenue represents a surprise of +8.91% over the Zacks Consensus Estimate of $538.1 million. With the consensus EPS estimate being $0.12, the EPS surprise was +66.67%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Hims & Hers Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Monthly Online Revenue per Average Subscriber: $84 versus the two-analyst average estimate of $76.47.
- Subscribers (end of period): 2.37 million versus the two-analyst average estimate of 2.31 million.
- Revenue- Wholesale: $9.65 million versus the five-analyst average estimate of $11.06 million.
- Revenue- Online: $576.36 million compared to the $527.37 million average estimate based on five analysts.
View all Key Company Metrics for Hims & Hers Health here>>>
Shares of Hims & Hers Health have returned +57.1% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Hims & Hers Health, Inc. (HIMS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
